Technology | May 01, 2013

InterValve Receives 510(k) Clearance for V8 Aortic Valvuloplasty Balloon Catheter

 V8 Aortic Valvuloplasty Balloon Catheter InterValve

May 1, 2013 — InterValve Inc. announced that it has received 510(k) clearance to market the new V8 Aortic Valvuloplasty Balloon Catheter in the United States.

The V8 catheter is designed to be used in stand-alone balloon aortic valvuloplasty (BAV), and pre-dilation during transcatheter aortic valve replacement (TAVR) procedures.

“These procedures are limited today by the use of dated, conventional balloon technologies. The shape and material properties of the V8 balloon catheter are designed to enhance both procedures through reduction in balloon movement and optimized leaflet expansion without over distention of the annulus,” said Mark Ungs, chief executive officer of InterValve.

The balloon catheter features a figure-8 shape balloon that enables the bulbs at either end of the balloon to “lock” into either side of the aortic annulus. This design has the potential to reduce the risk of balloon movement during dilatation, thereby reducing procedure and ischemic time.

The non-compliant material maintains the figure-8 shape throughout inflation, which allows for leaflet hyperextension, to create maximum valve area opening, without increasing the risk of over-stretching the annulus.

Lastly, the catheter is designed to inflate and deflate rapidly to reduce the duration of blood flow obstruction across the valve.

For more information:

Related Content

Baylis Medical and Siemens Co-Sponsor Transseptal Access Training Course
News | EP Lab| October 18, 2017
Baylis Medical Co. Inc. and Siemens Healthineers are co-sponsoring a first-of-its kind training program aimed at...
Societies Issue New Performance and Quality Measures for Treating Patients with Heart Attack
News | Cath Lab| October 17, 2017
The American College of Cardiology and the American Heart Association recently released updated clinical performance...
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Appropriate Use Criteria Published for Valvular Heart Disease Imaging Tests
News | Clinical Decision Support| October 16, 2017
The American College of Cardiology (ACC), along with several partnering societies, recently released appropriate use...
Dee Dee Wang runs Henry Ford Hospital's 3D printing lab for its complex structural heart cardiology program.

Dee Dee Wang, M.D., runs Henry Ford Hospital's 3-D printing lab that supports its complex structural heart program.

Feature | 3-D Printing| October 13, 2017 | Dave Fornell
Three-dimensional (3-D) printed anatomic models created from a patient’s computed tomography (CT), magnetic resonance...
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
Videos | Chronic Total Occlusion (CTO)| October 09, 2017
Bill Lombardi, M.D., director of complex coronary artery interventions at the University of Washington, discusses the
BTG Acquires Roxwood Medical
News | Business| October 05, 2017
BTG plc announced it has acquired Roxwood Medical, provider of advanced cardiovascular specialty catheters used in the...
TVA Medical Receives CE Mark for Next-Generation EverlinQ 4 EndoAVF System
News | Vascular Access| October 04, 2017
TVA Medical Inc. announced that its everlinQ 4 endoAVF System has received CE Mark in the European Union. The...
Reflow Medical's Wingman Crossing Catheter Receives FDA Clearance for Coronary Indication
News | Catheters| October 02, 2017
October 2, 2017 — Reflow Medical Inc. announced that the company has received 510(k) clearance from the U.S.
Overlay Init